Technology Appraisal Guidance No. 99
Source: National Institute for Health and Care Excellence
This guidance considers the use of basiliximab, daclizumab, tacrolimus, mycophenolate (mofetil and sodium) and sirolimus in relation to a standard triple therapy regimen of ciclosporin, azathioprine and a corticosteroid following renal transplantation in children and adolescents.
1.1 Basiliximab or daclizumab, used as part of a ciclosporin-based immunosuppressive regimen, are recommended as options for induction therapy in the prophylaxis of acute organ rejection in children and adolescents undergoing renal transplantation, irrespective of immunological risk. The induction therapy (basiliximab or daclizumab) with the lowest acquisition cost should be used, unless it is contraindicated.
1.2 Tacrolimus is recommended as an alternative option to ciclosporin when a calcineurin inhibitor is indicated as part of an initial or a maintenance immunosuppressive regimen for renal transplantation in children and adolescents. The initial choice of tacrolimus or ciclosporin should be based on the relative importance of their side-effect profiles for the individual patient.
1.3 Mycophenolate mofetil (MMF) is recommended as an option as part of an immunosuppressive regimen for child and adolescent renal transplant recipients only when:
- there is proven intolerance to calcineurin inhibitors, particularly nephrotoxicity which could lead to risk of chronic allograft dysfunction, or
- there is a very high risk of nephrotoxicity necessitating the minimisation or avoidance of a calcineurin inhibitor until the period of high risk has passed.
1.4 The use of MMF in corticosteroid reduction or withdrawal strategies for child and adolescent renal transplant recipients is recommended only within the context of randomised clinical trials.
1.5 Mycophenolate sodium (MPS) is currently not recommended for use as part of an immunosuppressive regimen in child or adolescent renal transplant recipients.
1.6 Sirolimus is not recommended for children or adolescents undergoing renal transplantation except when proven intolerance to calcineurin inhibitors (including nephrotoxicity) necessitates the complete withdrawal of these treatments.
1.7 As a consequence of following this guidance, some medicines may be prescribed outside the terms of their UK marketing authorisation. Healthcare professionals prescribing these medicines should ensure that children and adolescents receiving renal transplants and/or their legal guardians are aware of this, and that they consent to the use of these medicines in these circumstances.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://www.nice.org.uk/guidance/ta99
Copies of the document can also be obtained by contacting 0845 003 7783 or emailing email@example.com and quoting reference number N1024.
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: firstname.lastname@example.org
Immunosuppressive Therapy for Renal Transplantation in Children and Adolescents.
Issue Date: April 2006
Review Date: March 2009